ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors

Scientists screened a patient-derived xenograft library to identify small cell lung cancer as a tumor type with enhanced sensitivity to calicheamicin antibody–drug conjugates. They developed an antibody targeting seizure-related homolog 6 (SEZ6) that is rapidly internalized upon receptor binding and, when conjugated to the calicheamicin linker drug, drives potent tumor regression in vitro and in vivo.